SUMMIT European Cannabis Insights Summit 2026 — Exclusive industry intelligence Register Now
EVENT Cannabis Europa London 2026 — Europe's cannabis industry unites Get Tickets

Recent Searches

    LP’s ‘bleeding cash’ while awaiting legalization

    By

    MSO > LPs

    Large US MSOs are trading at higher revenue multiples than Canadian LPs: Viridian

    Finally, after trending downward for the last year, American MSOs are trading at higher revenue multiples than Canadian LPs, per Viridian Capital’s latest chart of the week.

    When President Biden was elected, hopes for federal legalization sent multiples soaring—particularly among Canadian licensed producers (LPs). Now that five of the 10 largest Canadian LPs project negative EBITDA for the next 12 months, that has changed.

    “The current constrained financing market has revealed the weakness of the LP strategy: waiting for legalization while bleeding cash,” wrote CFA Frank Colombo, director of data analytics at Viridian. 

    Name-checking Canopy Growth, Cronos and Aurora, he wrote, “It is becoming increasingly apparent that some of the formerly robust Canadian LPs may not have the financial capacity to make a sizable US market entrance by the time it is allowed. Some continue to burn so much cash that long-term survivability is in question.”


    Enjoy Cannabis Daily each morning at 7 a.m.

    NO STANDARDIZATION

    Cannabis safety standards vary state-to-state

    Without federal oversight, states are implementing different lab-testing standards pertaining to issues like contaminants and potency, writes Bloomberg.

    While the methodology and requirements for safety testing every other product sold in the US, from over-the-counter medications to food products, are regulated federally, cannabis is not. 

    “Standardization across product forms, product naming, labelling and testing would simplify our business,” said Dennis Curran, CEO of Acreage Holdings.. “But it would be of greatest benefit to consumers, who face a confusing array of products and standards in different states.”


    LEADERBOARD

    Canada’s latest market share winners and losers: Hifyre

    Citing Hifyre’s latest cannabis market share data reported by Cantor, MJBizDaily international editor Matt Lamers tweeted the following update: 

    • HEXO market share declined from 14% to 9.8% since Feb.-April of 2021
    • Organigram rose to 7.9% from 5%
    • Tilray was down from 18% to 7.7% 
    • Canopy was down from 15% to 6.7% 
    • Pure Sunfarms nudged up from 6% to 6.1% 
    • Auxly also increase slightly rom 4% to 5.5% 
    • Decibel rose from 3.2% to 4.2%
    • Cronos also rose from 3.2% to 4.2%
    • And newcomer BZAM earned 3.1% 

    Hifyre collects data from four provinces: Ontario, Alberta, Saskatchewan, and BC.


    Mike Hoban

    Share Article

    The Briefing / Newsletter

    Insights
    you don't want
    to miss.

    A comprehensive, thoughtfully curated overview of the stories defining today's cannabis sector — breaking news, investigative features, expert commentary, and context-rich analysis to help you navigate events with clarity and confidence.

    • Policy & regulation
    • Markets & deals
    • Clinical & science
    Subscribe free

    Related news